Cohort comparisons are available for a subset of clinical and molecular features.
* Please be aware that it may not be possible to present the results of all analyses due to small cohort sizes
Age at Diagnosis
Breast cancer patients of differing age groups have been shown to present with distinct pathological and clinical features.
Patients have been stratified into three age groups:
<40 years
40-59 years
>60 years
Projects: TCGA, BRCA EU, BRCA FR, BRCA KR, BRCA UK, BRCA US, GEL, Spatial
Genetic Ancestry
Biological differences in the profile of breast cancer have been reported between ethnic groups.
Researchers can compare results from five populations:
European (EUR)
African (AFR)
South Asian (SAS)
East Asian (EAS)
Admix American (AMR)
Projects: TCGA, GEL
Menopausal Status
Menopausal status is a risk factor of breast cancer and impacts therapeutic management of disease.
Where possible, patients available from projects have been stratified into three categories:
pre-menopausal
post-menopausal
peri-menopausal
Projects: TCGA, GEL, Spatial
ER Status
The hormone receptor status of breast tumours is routinely evaluated
to help guide the clinical management of patients and predict potential response to hormone therapy.
Patients within each project have been stratified into cohorts based on their ER status.
ER positive
ER negative
Projects: TCGA, BRCA EU, GEL, Spatial
HER2 Status
The Her2 status of breast tumours is routinely evaluated
to help guide the clinical management of patients and predict whether these tumours would be amenable to targeted therapies.
Patients within each project have been stratified into cohorts based on their Her2 status.
Her2 positive
Her2 negative
Projects: TCGA, BRCA EU, BRCA FR, GEL, Spatial